Title:
DOUBLE-STRANDED RIBONUCLEIC ACID FOR INHIBITING ANGPTL3 GENE EXPRESSION, AND MODIFIER, CONJUGATE, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/027518
Kind Code:
A1
Abstract:
The present disclosure relates to a double-stranded ribonucleic acid for inhibiting ANGPTL3 gene expression, and a modifier, a conjugate, and use thereof. Specifically, the present disclosure relates to a double-stranded ribonucleic acid, a double-stranded ribonucleic acid modifier, a double-stranded ribonucleic acid conjugate, a pharmaceutical composition and use for inhibiting ANGPTL3 gene expression, and a method for inhibiting intracellular ANGPTL3 gene expression. The double-stranded ribonucleic acid provided in the present disclosure can bind in cells to form an RNA-induced silencing complex (RISC), which cleaves the mRNA transcribed by the ANGPTL3 gene, efficiently and specifically inhibiting the expression of the ANGPTL3 gene. The double-stranded ribonucleic acid is used for treating diseases associated with ANGPTL3 gene-mediated metabolic disorders, and has important application prospects in clinical disease treatment.
Inventors:
WANG SHUCHENG (CN)
HUANG HE (CN)
WANG YAN (CN)
LIN GUOLIANG (CN)
CHAN YUNXIA (CN)
GENG YUXIAN (CN)
WANG XIAOJUN (CN)
RONG MEI (CN)
HUANG HE (CN)
WANG YAN (CN)
LIN GUOLIANG (CN)
CHAN YUNXIA (CN)
GENG YUXIAN (CN)
WANG XIAOJUN (CN)
RONG MEI (CN)
Application Number:
PCT/CN2023/108634
Publication Date:
February 08, 2024
Filing Date:
July 21, 2023
Export Citation:
Assignee:
BEIJING WINSUNNY PHARMACEUTICAL CO LTD (CN)
International Classes:
A61K31/713; A61K31/7125; A61P3/00; C07H21/02
Domestic Patent References:
| WO2022079222A1 | 2022-04-21 | |||
| WO2022068923A1 | 2022-04-07 |
Foreign References:
| CN107743522A | 2018-02-27 | |||
| CN111343994A | 2020-06-26 | |||
| CN110945130A | 2020-03-31 | |||
| CN111973617A | 2020-11-24 |
Attorney, Agent or Firm:
LINDA LIU & PARTNERS (CN)
Download PDF:
Previous Patent: LAMP
Next Patent: SUBLINGUAL TABLET AND APPLICATION THEREOF IN DESENSITIZATION THERAPY DRUG
Next Patent: SUBLINGUAL TABLET AND APPLICATION THEREOF IN DESENSITIZATION THERAPY DRUG